| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
|
|---|---|
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Lactation Use Currently, there is no information regarding the excretion of cytarabine into breast milk. However, the drug has a short half-life after intravenous administration, only 2 to 3 hours, and is therefore cleared from breast milk within one day of intravenous administration. Information regarding the use of cytarabine during lactation is very limited. One case involved a mother who began breastfeeding 3 weeks after receiving intravenous injections of cytarabine, mitoxantrone, and etoposide, with no significant adverse reactions observed in the infant. Following intrathecal injection of liposomal cytarabine, the drug concentration in plasma is almost undetectable, making it unlikely that a clinically significant dose would be present in breast milk. ◉ Effects on Breastfed Infants One mother received a dose of 6 mg/m² three times daily. The patient received intravenous mitoxantrone, along with daily intravenous etoposide 80 mg/m² and cytarabine 170 mg/m². Three weeks after the third injection of mitoxantrone, she resumed breastfeeding, at which point mitoxantrone was still detectable in her breast milk. The infant showed no obvious abnormalities at 16 months of age. However, cytarabine is unlikely to be present in breast milk three weeks after breastfeeding was discontinued. ◉ Effects on lactation and breast milk As of the revision date, no relevant published information was found. |
| References | |
| Additional Infomation |
Cytosar, a nucleoside analogue, has been reported to be detected in Fritillaria taipaiensis, Fritillaria walujewii, and other organisms with relevant data. Cytosar is primarily used to treat leukemia, especially acute non-lymphocytic leukemia. It is an antimetabolite and antitumor drug that inhibits DNA synthesis. Its action is specific to the S phase of the cell cycle. It also possesses antiviral and immunosuppressive properties. (From Martindale, The Extra Pharmacopoeia, 30th edition, p. 472) See also: Cystine (note moved to); Cytosar (note moved to).
|
| Molecular Formula |
C9H13N3O5
|
|---|---|
| Molecular Weight |
243.217
|
| Exact Mass |
245.098
|
| CAS # |
478511-21-6
|
| Related CAS # |
Cytidine;65-46-3
|
| PubChem CID |
596
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
-2.1
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
17
|
| Complexity |
383
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
NC1N=C(=O)N(=CC=1)C2C(O)C(O)C(C([2H])([2H])O)O2
|
| InChi Key |
UHDGCWIWMRVCDJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)
|
| Chemical Name |
4-amino-1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1115 mL | 20.5575 mL | 41.1150 mL | |
| 5 mM | 0.8223 mL | 4.1115 mL | 8.2230 mL | |
| 10 mM | 0.4112 mL | 2.0558 mL | 4.1115 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
